Алкогольний фіброз печінки: сучасний стан проблеми

T. D. Zvyagintseva, A. I. Chernobay

Анотація


Представлено дані щодо патогенетичних механізмів розвитку фіброгенезу та алкогольного фіброзу печінки. Визначено чинники прогресування та звортності хвороби. Показано роль препарату ­«Гепаризин» як комбінованого гепатопротектора, який має антифібротичну активність, протизапальну, мембранопротекторну, антиоксидантну і антитоксичну дію.

Ключові слова


печінка; фіброз; алкогольний фіброз печінки; зірчасті клітини; цитокіни; «Гепаризин»

Повний текст:

PDF (Русский)

Посилання


Balashova AA. Rol’ immuno-vospalitel’nyh izmenenij v otsenke alkogol’nogo porazheniya pecheni [The role of immune-inflammatory changes in the evaluation of alcoholic liver damage].Аbstract of thesis of dis. … of cand. мed. sciences. (Russian). М., 2017.

Golovanova EV. Mechanisms of fibrosis in chronic liver diseases and the possibility of antifibrotic therapy (Russian) Соnsilium Medicum [Соnsilium physician](Russian). 2014;8:52-59.

Zvyagintseva TD, Chernobay AI. Modern views on the problem of noncirrhotic liver fibrosis (Russian)Mistectvo licuvannуа [Art of treatment] (Ukrainian). 2017;6/7:4-14.

Zvyagintseva TD, Chernobay AI New possibilities of hepatoprotection for non-alcoholic and alcoholic steatohepatitis (Russian). Рraktykujuchyj licar [Practicing doctor] (Ukrainian). 2015;1:46-53.

Zvyagintseva TD, Chernobay AI, Kharchenko NV. Khronicheskie zabolevaniya pecheni. Rukovodstvo dlya vrachej. 3-e izd. Chronic liver diseases. A guide for doctors. 3rd ed. (Ukrainian). Kharkiv: Printing house Madrid, 2016:260.

Ivashkin V, T., Pavlov CS. Fibros pecheni [Fibrosis of the liver] (Russian). M.: Geotar-Media, 2011:168.

Korsunskaya IM, Piruzyan AL, Sakaniya LR et al. The role of glycyrrhizic acid in the pathogenesis of psoriatic disease. Effectivnaya farmacoterapiуа[Effective pharmacotherapy]. (Russian). 2016;13:24-31.

Kurysheva MA. Fibrosis of the liver: past, present, future. RMJ [RMJ]. (Russian). 2010;28:1713-1717.

Nikitin IG, Baikova IE, Volynkina VM et al. Experience in the use of glycyrrhizic acid in the treatment of patients with alcoholic liver disease RJGGC [RJGGC]. (Russian). 2009;1, Т. 19:53-58.

Orlov Yu.V., Sinyachkin DA, Khalimov Yu.S. et al. Modern state of the problem of treatment of toxic hepatitis and liver fibrosis Gepatologiya [Hepatology]. (Russian). 2017;18:488-513.

Hookhlina OS, Antonov AA, Mandryk OE. Influence of glycyrhizin in combination with glycine and methionine on the state of extracellular matrix components in patients with non-alcoholic steatohepatitis due to the comorbidity of the matrix and the intensity of liver fibrosis in patients with non-alcoholic steatohepatitis for comorbidity with chronic kidney disease Suchasna gastroenterologiya [Modern gastroenterology]. (Ukrainian). 2017;5 (97):29-33.

Chernyavsky VV. Inflammatory process in chronic liver diseases: possible therapeutic approaches Рraktykujuchyjlicar [Practicing doctor] (Ukrainian). 2013;3:38-42.

Alba R, Compare D, Angrisani D et al. Alcoholic disease: liver and beyond. World J Gastroenterol. 2014;20 (40):14652-14659.

Christian Trautwein L, Friedman S, Schuppan D et al. Hepatic fibrosis: concept to treatment. J Hepatol. 2015;62:15-24.

Chuan-tao Tu, Jing Li, Fu-ping Wang et al. Glycyrrhizin regulates CD4+T cell response during liver fibrogenesis via JNK, ERK and PI3K/AKT pathway. Intern Immunopharmacol. 2012;14:410-421.

Fiore C, Eisenhut M, Krausse R et al. Antiviral effects of Glycyrrhiza species. Phytother Res. 2008;22:141-148.

Hanafy АS. Non-invasive assessment of fibrosis progression in non-alcoholic fatty liver disease. J Hepatol. 2016;64(2):473.

Julie P, Neil Guha I, Harris S. Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver disease. Comparative Hepatol. 2012;1:1-15.

Jian-yuan Li, Hong-yan Cao, Ping Liu et al. Glycyrrhizic acid in the treatment of liver diseases: Literature review. Biomed Res Int. 2014;2014. 872139.

Kumada H. Long-term gtreatment of chronic hepetitis C with glycyrrhizin (SNMC) for preventis liver chirrosis and hepatocellular carcinoma. Oncol. 2002;62:94-100.

Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Clin Gastroenterol. 2011;25:195-206.

Lech C, Panasiuk A. Liver fibrosis markers in alcoholic liver disease. World J Gastroenterol. 2014;20 (25):8018-8023.

Li JY, Cao HY, Liu P et al. Glycyrrhizic acid in the treatment of liver diseases: literature review. Biomed Res Int. 2014;872139.

Liver fibrosis: The next goal of targeted therapy?. EASL Monothematic Conference (Porto, Portugal, 17-18 June, 2016):181.

Meng Wei, Yu Liang-zhu,Wang L. Effects of compound glycyrrhizin on liver function in patients with alcoholic liver disease:a meta-analysis. China Pharmacy. 2013;12:108-115.

Naveau S, Essoh BM, Ghinoiu M et al. Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease. Eur J GastroenterolHepatol. 2014;26, N 4:404-411.

Pragati L, Ganesh KB, Kothiyal P. Hepatic stellate cells as a target for the treatment of liver fibrosis. Int J Pharma Res. 2015;4(7):32-37.

Scott LF. Mechnisms of hepatic fibrogenesis. Gastroenterol. 2008;134(6):1655-1669.

Yue Sihong. Treatment of liver cirrhosis with compound glycyrrhizin (252 cases). J Binzhou Medical College. 1998;21(6):556.

Wang Juntao, Yu Shaojun, Xiao Wei Clinical application of compound glycyrrhizin in liver diseases. J China Pharm. 2002;13(8):500-501.

Znanje Znanje. The improvement function of compound glycyrrhizin (SNMC) on liver function in patients with cirrhosis. Acta Academiae Medicinae Nei Мongol. 2004;26:1-6.




© Сучасна гастроентерологія, 2018
© ТОВ «ВІТ-А-ПОЛ», 2018